Clinical Trial Update: PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update evaluating a PET-adapted combination of Brentuximab Vedotin and Pembrolizumab with doxorubicin and dacarbazine for class…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Adcetris (brentuximab vedotin) (brentuximab vedotin)
• Adriamycin (doxorubicin) (doxorubicin)
• DTIC-Dome (dacarbazine) (dacarbazine)
• Keytruda (Pembrolizumab) (pembrolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Hodgkin Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING